Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services
1. FDA approved LYMPHIR for CTCL treatment, effective April 1, 2025.
FAQ
Why Bullish?
The FDA approval can lead to increased revenues and market opportunity for CTOR.
How important is it?
FDA approvals are significant for biotech firms, impacting stock prices positively.
Why Long Term?
Approval often leads to sustained sales growth as product adoption increases over time.